Montréal, Canada – In a significant leap forward for cardiovascular care, the Institut de Cardiologie de Montréal (ICM) has inaugurated a cutting-edge Centre de simulation avancée en thérapie valvulaire – an advanced simulation center for valve therapy. This marks the first such facility on the American continent, poised to revolutionize the training of medical professionals and accelerate advancements in the treatment of heart valve disease. The opening, which took place on February 27, 2026, underscores Montréal’s growing reputation as a global hub for medical innovation.
Heart valve disease affects millions worldwide, ranging from relatively mild conditions to life-threatening emergencies. Traditionally, training for complex valve interventions has relied on observation and limited hands-on experience. The new center addresses this challenge by providing a highly realistic and safe environment for surgeons and cardiologists to hone their skills. The initiative builds upon the foundation laid by the opening of the ICM’s Centre de thérapie valvulaire less than a year ago, demonstrating a rapid and sustained commitment to improving patient outcomes.
A New Era in Valve Therapy Training
The Centre de simulation avancée en thérapie valvulaire is equipped with state-of-the-art cardiovascular simulation systems acquired from Simulands, a Swiss company specializing in high-fidelity medical simulation technology. According to Info de Laval, these systems allow medical teams to practice intricate procedures – including transcatheter aortic valve implantation (TAVI) and mitral valve repair using devices like MitraClip and TriClip – in a controlled setting, minimizing risks to patients and maximizing surgical precision.
The ICM’s approach is unique in its integration of cardiology and cardiac surgery, fostering a collaborative environment that is crucial for optimal patient care. The clinic specializes in treating patients with high-risk heart valve disease, offering innovative transcatheter valve implantation techniques. The center will focus on training for a range of interventions, encompassing both transcatheter therapies and complex repair procedures, reflecting the rapidly evolving landscape of cardiovascular medicine.
Doubling Treatment Capacity by 2028
The establishment of the simulation center is not merely about improving training. it’s a strategic move to significantly increase the ICM’s capacity to treat heart valve disease. The institute aims to double its treatment volume by 2028, a goal that will be facilitated by accelerated training, standardized practices, and the development of clinical expertise. As reported by Info de Laval, the ICM is positioning itself as a leading international center for structural cardiology and aspires to turn into a top-ten valve therapy center globally.
The simulation center will offer comprehensive training covering all aspects of structural cardiology interventions. This includes not only the technical skills required for valve therapies but also the decision-making processes involved in patient selection and treatment planning. The emphasis on standardization will ensure that all medical professionals adhere to the highest quality standards, leading to more consistent and predictable outcomes.
The Transcatheter Valve Therapy Clinic at ICM
The Institut de Cardiologie de Montréal’s (ICM) transcatheter valve therapy (TVT) clinic provides specialized care for patients at high risk of heart valve disease. According to the ICM website, the clinic offers services for patients with aortic stenosis, mitral regurgitation, or tricuspid regurgitation who may benefit from innovative transcatheter valve implantation techniques, such as TAVI, and mitral or tricuspid valve leaflet repair using devices like MitraClip or TriClip. The clinic operates from 8:00 AM to 4:00 PM.
To access the TVT clinic, patients require a referral from a specialist physician, including family doctors, internists, cardiologists, or cardiac surgeons. All patients undergo a thorough evaluation by a multidisciplinary team before treatment decisions are made. Requests for consultation must be submitted by fax to 514-593-2158 and include the patient’s full name, first name, complete address, health insurance number with expiration date, primary phone number, cell phone number, email address, and mother’s maiden name.
Impact on Patient Care and Medical Advancement
The establishment of this advanced simulation center represents a paradigm shift in medical training. By providing a safe and realistic environment for practice, the ICM is empowering its medical teams to deliver the highest quality care to patients with heart valve disease. The center’s focus on innovation and collaboration will also drive advancements in the field, leading to new and improved treatment options.
The benefits extend beyond the ICM itself. By attracting leading medical professionals from around the world, the center will contribute to the growth of Montréal’s reputation as a global center of excellence in cardiovascular medicine. The availability of advanced training opportunities will also help to address the shortage of skilled specialists in this critical field.
Looking Ahead
The ICM’s commitment to innovation doesn’t stop with the simulation center. The institute continues to invest in research and development, exploring new technologies and therapies to improve the lives of patients with heart disease. The next major milestone will be the ongoing evaluation of the center’s impact on treatment capacity and patient outcomes, with data expected to be published in late 2027.
The inauguration of the Centre de simulation avancée en thérapie valvulaire is a testament to the dedication and vision of the Institut de Cardiologie de Montréal. It is a significant step forward in the fight against heart valve disease and a beacon of hope for patients around the world.
What are your thoughts on this new center? Share your comments below, and please share this article with your network to raise awareness about the advancements in cardiovascular care.